NACT exerts the greatest potential in human epidermal growth factor receptor 2 (HER2) positive and triple-negative [estrogen receptor (ER) negative, progesterone receptor (PgR) negative, and HER2 negative] breast malignancies (2–4). This evidence concerns the gene PGR and medical procedure.